Wide Ranks

IRD

Opus Genetics, Inc.

1.05

Top Statistics
Market Cap 33 M Forward PE -1.29 Revenue Growth -67.60 %
Current Ratio 6.63 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.1180 Enterprise / Revenue -0.4160 Price To Sales Trailing12 Months 3.96
Profitability
Profit Margins 0.00 % Operating Margins -207.11 %
Balance Sheet
Total Cash 36 M Total Cash Per Share 1.16 Total Debt
Total Debt To Equity Current Ratio 6.63 Book Value Per Share 1.31
All Measures
Short Ratio 394.00 % Message Board Id finmb_560534013 Shares Short Prior Month 930639
Return On Equity -0.6430 City Farmington Hills Uuid 8539a4cc-99e3-3203-acff-498622533243
Previous Close 1.09 First Trade Date Epoch Utc 1 B Book Value 1.31
Volume 195060 Price To Book 0.8021 Last Split Date 1 B
Fifty Two Week Low 0.8500 Total Cash Per Share 1.16 Total Revenue 8 M
Shares Short Previous Month Date 1 B Target Median Price 9.50 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -207.11 % Target Mean Price 10.50
Net Income To Common -27192000 Ask 1.10 Short Percent Of Float 0.0227
Implied Shares Outstanding 31 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 239710 Average Volume10days 239710 Total Cash 36 M
Next Fiscal Year End 1 B Revenue Per Share 0.3370 Held Percent Insiders 0.1581
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.09 Target Low Price 8.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 1.21 Open 1.08 Free Cashflow -8284250
State MI Dividend Yield 0.00 % Return On Assets -0.3895
Time Zone Short Name EST Trailing Eps -1.09 Day Low 1.03
Address1 37000 Grand River Avenue Shares Outstanding 31 M Price Hint 4
Target High Price 15.00 Website https://opusgtx.com 52 Week Change -0.6557
Average Volume 139390 Forward Eps -0.8600 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 656.30 % Last Split Factor 1:4
Regular Market Day High 1.09 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 3.40 Day High 1.09 Shares Short 685011
Regular Market Open 1.08 Industry Key biotechnology Bid 1.01
Earnings Growth 0.00 % Enterprise To Revenue -0.4160 Revenue Growth -67.60 %
Shares Percent Shares Out 0.0217 Operating Cashflow -13590000 Currency USD
Time Zone Full Name America/New_York Market Cap 33 M Is_nasdaq_100 False
Zip 48335 Quote Type EQUITY Industry Biotechnology
Long Name Opus Genetics, Inc. Regular Market Day Low 1.03 Held Percent Institutions 0.0805
Current Price 1.05 Address2 Suite 120 Enterprise To Ebitda 0.1180
Financial Currency USD Current Ratio 6.63 Gross Margins -61.88 %
Industry Disp Biotechnology Number Of Analyst Opinions 4 Country United States
Float Shares 27 M Two Hundred Day Average 1.64 Ir Website http://www.rexahn.com/cms/index.php/investor-relations/
Enterprise Value -3488120 Price To Sales Trailing12 Months 3.96 Forward PE -1.29
Regular Market Volume 195060 Ebitda -29466500 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.

The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.

Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.

The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications.

The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.